Rocket Pharmaceuticals (RCKT) PT Lowered to $7 at Leerink Partners

Leerink Partners analyst Mani Foroohar lowered the price target on Rocket Pharmaceuticals (NASDAQ: RCKT) to $7.00 (from $9.00) while maintaining a Market Perform rating.

The analyst comments "This morning, RCKT announced via 8-K that the BLA for RP-L102 in Fanconi Anemia (FA) has been voluntarily withdrawn. The decision comes on the heels of withdrawing RPL102’s MAA for European approval in July, and RCKT’s strategic prioritization at 2Q25 earnings where management announced paused development of RP-L102 and RP-L301 (in PKD) and were pursuing partnerships (here). We update our model – lowering RP-L102 PoS to 0% and OpEx to reflect savings – reducing our PT to $7 (from $9) and reiterate MP."

You May Also Be Interested In

• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• Cantor Fitzgerald Reiterates Overweight Rating on Applied Materials (AMAT)
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c